Cost estimation of medicinal treatment of hypertension in the Kyrgyz Republic with the view of creating possible drug supply mechanisms ensuring free-of-charge HTN treatment

Abdraimova A., Urmanbetova A., Borchubaeva G., Azizbekova J.

Hypertension is the leading cause of mortality and disability in Kyrgyzstan among other cardio-vascular diseases. It was demonstrated that share of hypertension combined with hyperlipidemia and coronary heart disease that contribute to mortality and disability rates from CVDs measures up to 80% . Hypertension incidence continues to grow reaching from 30.1% in adult population to 34.1% in the age group of 18+ . Den Sooluk Health Reform  Program segregates measures on improvement of hypertension detection and control into separate group of performance indicators on CVD which in combination with other performance indicators are expected to lead to annual 1% reduction in CVD mortality rates. Kyrgyzstan has made tremendous efforts to improve primary health care. Hypertension control was emphasized in this process as one of the monitored conditions. In addition, State-guaranteed Benefit Package (SGBP) and Additional Drug Package for insured population at outpatient level were designed to ensure affordability of health services on detection and treatment of various conditions including hypertension. The focus of this research was to study the issue of affordability of antihypertensive drugs, i.e. cost of drug therapy, since effective hypertension control can improve health outcomes by reducing acute CVD cases such as stroke and myocardial infarction and be cost-effective for the health system by reducing hospitalization rates.

Cost estimation of medical treatment of hypertension in the Kyrgyz Republic with the view of creating possible drug supply mechanisms ensuring HTN treatment for free(PDF-1)